|
시장보고서
상품코드
1988615
위탁 개발 및 생산 기관(CDMO) - 세계 시장 점유율과 순위, 전체 판매 및 수요 예측(2026-2032년)Contract Development and Manufacturing Organizations (CDMOs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032 |
||||||
QYResearch
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.
세계의 위탁 개발 및 생산 기관(CDMO) 시장 규모는 2025년에 146억 3,100만 달러로 추정되며, 2026년부터 2032년까지 CAGR 7.24%로 성장하여 2032년에는 2,421억 3,500만 달러에 달할 것으로 예측됩니다.
북미 위탁 개발 및 생산 기관(CDMO) 시장은 2025년에 443억 3,600만 달러로 평가되었으며, 2026년부터 2032년까지 6.43%의 CAGR로 2032년까지 693억 6,700만 달러에 달할 것으로 예상됩니다.
아시아태평양의 위탁 개발 및 생산 기관(CDMO) 시장은 2025년에 535억 7,700만 달러로 평가되었으며, 2026년부터 2032년까지 7.88%의 CAGR로 2032년까지 922억 9,100만 달러에 달할 것으로 예상됩니다.
위탁 개발 및 생산 기관(CDMO) 시장의 세계 주요 기업으로는 Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem 등을 들 수 있습니다. 2025년에는 상위 5개 기업의 매출액이 시장의 약 14.15%를 차했습니다.
이 보고서는 위탁 개발 및 생산 기관(CDMO) 세계 시장에 대한 종합적인 관점을 제공하며, 총매출액, 주요 기업의 시장 점유율 및 순위, 지역별, 국가별, 유형별, 용도별 분석 정보를 제공합니다.
이 보고서는 2025년을 기준 연도, 2021년에서 2032년까지의 과거 데이터와 예측 데이터를 포함하는 매출액(백만 달러)을 기준으로 위탁 개발 및 생산 기관(CDMO) 시장 규모, 추정치 및 예측을 제시합니다. 이 보고서는 정량적 분석과 정성적 분석을 결합하여 독자들이 성장 전략을 수립하고, 경쟁 상황을 평가하고, 현재 시장에서의 위치를 파악하고, 위탁 개발 및 생산 기관(CDMO)에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Lonza
- Catalent
- Thermo Fisher Scientific
- Samsung Biologics
- Fareva
- WuXi AppTech
- WuXi Biologics
- Siegfried
- FUJIFILM Diosynth Biotechnologies
- Vetter
- Boehringer Ingelheim
- AGC Pharma Chemicals
- Pfizer CentreOne
- Delpharm
- Curia
- Aenova
- Recipharm
- Piramal
- Asymchem
- Strides Pharma
- Porton
- NextPharma
- Jubilant
- Euroapi
- Famar
- Eurofins
- Avid Bioservices
- Alcami
- BioVectra
- CPL
유형별 부문
- API CDMO
- FDF CDMO
- 포장 CDMO
- 임상 CDMO
용도별 부문
- 제약회사
- 바이오테크놀러지 기업
- 기타
지역별 소비량
- 북미
- 미국
- 캐나다
- 멕시코
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 러시아
- 기타 유럽
- 남미
- 브라질
- 기타 남미
- 중동 및 아프리카
- 중동
- 아프리카
자주 묻는 질문
The global market for Contract Development and Manufacturing Organizations (CDMOs) was estimated to be worth US$ 14631 million in 2025 and is projected to reach US$ 242135 million, growing at a CAGR of 7.24% from 2026 to 2032.
The North American market for Contract Development and Manufacturing Organizations (CDMOs) was valued at US$ 44336 million in 2025 and is projected to reach US$ 69367 million by 2032, at a CAGR of 6.43% from 2026 to 2032.
The Asia-Pacific market for Contract Development and Manufacturing Organizations (CDMOs) was valued at $ 53577 million in 2025 and is projected to climb to US$ 92291 million by 2032, at a CAGR of 7.88% from 2026 to 2032.
The global key companies in the Contract Development and Manufacturing Organizations (CDMOs) market include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, etc. In 2025, the five largest players accounted for approximately 14.15% of revenue.
This report provides a comprehensive view of the global market for Contract Development and Manufacturing Organizations (CDMOs), covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Contract Development and Manufacturing Organizations (CDMOs) market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Contract Development and Manufacturing Organizations (CDMOs).
Market Segmentation
By Company
- Lonza
- Catalent
- Thermo Fisher Scientific
- Samsung Biologics
- Fareva
- WuXi AppTech
- WuXi Biologics
- Siegfried
- FUJIFILM Diosynth Biotechnologies
- Vetter
- Boehringer Ingelheim
- AGC Pharma Chemicals
- Pfizer CentreOne
- Delpharm
- Curia
- Aenova
- Recipharm
- Piramal
- Asymchem
- Strides Pharma
- Porton
- NextPharma
- Jubilant
- Euroapi
- Famar
- Eurofins
- Avid Bioservices
- Alcami
- BioVectra
- CPL
Segment by Type
- API CDMO
- FDF CDMO
- Packaging CDMO
- Clinical CDMO
Segment by Application
- Pharmaceutical Company
- Biotechnology Company
- Other
Consumption by Region
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe
- South America
- Brazil
- Rest of South America
- Middle East & Africa
- Middle East
- Africa
Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.
Chapter 2: Provides a detailed analysis of the Contract Development and Manufacturing Organizations (CDMOs) companies' competitive landscape-including sales and revenue shares, recent development plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market classification, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Contract Development and Manufacturing Organizations (CDMOs) revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Contract Development and Manufacturing Organizations (CDMOs) revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.
Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Contract Development and Manufacturing Organizations (CDMOs) Product Introduction
- 1.2 Global Contract Development and Manufacturing Organizations (CDMOs) Market Size Forecast (2021-2032)
- 1.3 Contract Development and Manufacturing Organizations (CDMOs) Market Trends & Drivers
- 1.3.1 Contract Development and Manufacturing Organizations (CDMOs) Industry Trends
- 1.3.2 Contract Development and Manufacturing Organizations (CDMOs) Market Drivers & Opportunities
- 1.3.3 Contract Development and Manufacturing Organizations (CDMOs) Market Challenges
- 1.3.4 Contract Development and Manufacturing Organizations (CDMOs) Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Contract Development and Manufacturing Organizations (CDMOs) Players Revenue Ranking (2025)
- 2.2 Global Contract Development and Manufacturing Organizations (CDMOs) Revenue by Company (2021-2026)
- 2.3 Key Companies' R&D and Operations Footprint and Headquarters
- 2.4 Key Companies Contract Development and Manufacturing Organizations (CDMOs) Product Offerings
- 2.5 Key Companies Founded Date Contract Development and Manufacturing Organizations (CDMOs)
- 2.6 Contract Development and Manufacturing Organizations (CDMOs) Market Competitive Analysis
- 2.6.1 Contract Development and Manufacturing Organizations (CDMOs) Market Concentration Rate (2021-2026)
- 2.6.2 Top 5 and Top 10 Global Companies by Contract Development and Manufacturing Organizations (CDMOs) Revenue in 2025
- 2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Contract Development and Manufacturing Organizations (CDMOs) revenue, 2025
- 2.7 Mergers & Acquisitions and Expansion
3 Segmentation Contract Development and Manufacturing Organizations (CDMOs) Market Classification
- 3.1 Introduction by Type
- 3.1.1 API CDMO
- 3.1.2 FDF CDMO
- 3.1.3 Packaging CDMO
- 3.1.4 Clinical CDMO
- 3.1.5 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Pharmaceutical Company
- 4.1.2 Biotechnology Company
- 4.2 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application
- 4.2.1 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application (2021-2032)
- 4.2.2 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application (2021-2032)
- 4.2.3 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application (%), 2021-2032
5 Segmentation by Region
- 5.1 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Region
- 5.1.1 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Region: 2021 vs 2025 vs 2032
- 5.1.2 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Region (2021-2026)
- 5.1.3 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Region (2027-2032)
- 5.1.4 Global Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Region (%), 2021-2032
- 5.2 North America
- 5.2.1 North America Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 5.2.2 North America Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Country (%), 2025 vs 2032
- 5.3 Europe
- 5.3.1 Europe Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 5.3.2 Europe Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Country (%), 2025 vs 2032
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 5.4.2 Asia Pacific Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Subregion (%), 2025 vs 2032
- 5.5 South America
- 5.5.1 South America Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 5.5.2 South America Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Country (%), 2025 vs 2032
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 5.6.2 Middle East & Africa Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Contract Development and Manufacturing Organizations (CDMOs) Sales Value Growth Trends, 2021 vs 2025 vs 2032
- 6.2 Key Countries/Regions Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.3 North America
- 6.3.1 North America Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.3.2 North America Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.3.3 North America Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.4 Europe
- 6.4.1 Europe Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.4.2 Europe Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.4.3 Europe Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.5 China
- 6.5.1 China Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.5.2 China Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.5.3 China Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.6 Japan
- 6.6.1 Japan Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.6.2 Japan Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.6.3 Japan Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.7 South Korea
- 6.7.1 South Korea Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.7.2 South Korea Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.7.3 South Korea Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.8 India
- 6.8.1 India Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.8.2 India Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.8.3 India Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
- 6.9 Southeast Asia
- 6.9.1 Southeast Asia Contract Development and Manufacturing Organizations (CDMOs) Sales Value, 2021-2032
- 6.9.2 Southeast Asia Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Type (%), 2025 vs 2032
- 6.9.3 Southeast Asia Contract Development and Manufacturing Organizations (CDMOs) Sales Value by Application, 2025 vs 2032
7 Key Players Profiles
- 7.1 Lonza
- 7.1.1 Lonza Company Details
- 7.1.2 Lonza Business Overview
- 7.1.3 Lonza Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.1.4 Lonza Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.1.5 Lonza Recent Development
- 7.2 Catalent
- 7.2.1 Catalent Company Details
- 7.2.2 Catalent Business Overview
- 7.2.3 Catalent Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.2.4 Catalent Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.2.5 Catalent Recent Development
- 7.3 Thermo Fisher Scientific
- 7.3.1 Thermo Fisher Scientific Company Details
- 7.3.2 Thermo Fisher Scientific Business Overview
- 7.3.3 Thermo Fisher Scientific Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.3.4 Thermo Fisher Scientific Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.3.5 Thermo Fisher Scientific Recent Development
- 7.4 Samsung Biologics
- 7.4.1 Samsung Biologics Company Details
- 7.4.2 Samsung Biologics Business Overview
- 7.4.3 Samsung Biologics Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.4.4 Samsung Biologics Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.4.5 Samsung Biologics Recent Development
- 7.5 Fareva
- 7.5.1 Fareva Company Details
- 7.5.2 Fareva Business Overview
- 7.5.3 Fareva Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.5.4 Fareva Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.5.5 Fareva Recent Development
- 7.6 WuXi AppTech
- 7.6.1 WuXi AppTech Company Details
- 7.6.2 WuXi AppTech Business Overview
- 7.6.3 WuXi AppTech Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.6.4 WuXi AppTech Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.6.5 WuXi AppTech Recent Development
- 7.7 WuXi Biologics
- 7.7.1 WuXi Biologics Company Details
- 7.7.2 WuXi Biologics Business Overview
- 7.7.3 WuXi Biologics Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.7.4 WuXi Biologics Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.7.5 WuXi Biologics Recent Development
- 7.8 Siegfried
- 7.8.1 Siegfried Company Details
- 7.8.2 Siegfried Business Overview
- 7.8.3 Siegfried Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.8.4 Siegfried Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.8.5 Siegfried Recent Development
- 7.9 FUJIFILM Diosynth Biotechnologies
- 7.9.1 FUJIFILM Diosynth Biotechnologies Company Details
- 7.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 7.9.3 FUJIFILM Diosynth Biotechnologies Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
- 7.10 Asymchem
- 7.10.1 Asymchem Company Details
- 7.10.2 Asymchem Business Overview
- 7.10.3 Asymchem Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.10.4 Asymchem Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.10.5 Asymchem Recent Development
- 7.11 Pfizer CentreOne
- 7.11.1 Pfizer CentreOne Company Details
- 7.11.2 Pfizer CentreOne Business Overview
- 7.11.3 Pfizer CentreOne Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.11.4 Pfizer CentreOne Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.11.5 Pfizer CentreOne Recent Development
- 7.12 Delpharm
- 7.12.1 Delpharm Company Details
- 7.12.2 Delpharm Business Overview
- 7.12.3 Delpharm Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.12.4 Delpharm Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.12.5 Delpharm Recent Development
- 7.13 Recipharm
- 7.13.1 Recipharm Company Details
- 7.13.2 Recipharm Business Overview
- 7.13.3 Recipharm Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.13.4 Recipharm Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.13.5 Recipharm Recent Development
- 7.14 AGC Pharma Chemicals
- 7.14.1 AGC Pharma Chemicals Company Details
- 7.14.2 AGC Pharma Chemicals Business Overview
- 7.14.3 AGC Pharma Chemicals Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.14.4 AGC Pharma Chemicals Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.14.5 AGC Pharma Chemicals Recent Development
- 7.15 Boehringer Ingelheim
- 7.15.1 Boehringer Ingelheim Company Details
- 7.15.2 Boehringer Ingelheim Business Overview
- 7.15.3 Boehringer Ingelheim Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.15.4 Boehringer Ingelheim Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.15.5 Boehringer Ingelheim Recent Development
- 7.16 Vetter Pharma
- 7.16.1 Vetter Pharma Company Details
- 7.16.2 Vetter Pharma Business Overview
- 7.16.3 Vetter Pharma Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.16.4 Vetter Pharma Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.16.5 Vetter Pharma Recent Development
- 7.17 Curia
- 7.17.1 Curia Company Details
- 7.17.2 Curia Business Overview
- 7.17.3 Curia Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.17.4 Curia Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.17.5 Curia Recent Development
- 7.18 Aenova
- 7.18.1 Aenova Company Details
- 7.18.2 Aenova Business Overview
- 7.18.3 Aenova Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.18.4 Aenova Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.18.5 Aenova Recent Development
- 7.19 Porton
- 7.19.1 Porton Company Details
- 7.19.2 Porton Business Overview
- 7.19.3 Porton Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.19.4 Porton Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.19.5 Porton Recent Development
- 7.20 Piramal
- 7.20.1 Piramal Company Details
- 7.20.2 Piramal Business Overview
- 7.20.3 Piramal Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.20.4 Piramal Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.20.5 Piramal Recent Development
- 7.21 Strides Pharma
- 7.21.1 Strides Pharma Company Details
- 7.21.2 Strides Pharma Business Overview
- 7.21.3 Strides Pharma Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.21.4 Strides Pharma Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.21.5 Strides Pharma Recent Development
- 7.22 NextPharma
- 7.22.1 NextPharma Company Details
- 7.22.2 NextPharma Business Overview
- 7.22.3 NextPharma Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.22.4 NextPharma Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.22.5 NextPharma Recent Development
- 7.23 Famar
- 7.23.1 Famar Company Details
- 7.23.2 Famar Business Overview
- 7.23.3 Famar Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.23.4 Famar Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.23.5 Famar Recent Development
- 7.24 Jubilant
- 7.24.1 Jubilant Company Details
- 7.24.2 Jubilant Business Overview
- 7.24.3 Jubilant Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.24.4 Jubilant Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.24.5 Jubilant Recent Development
- 7.25 Alcami
- 7.25.1 Alcami Company Details
- 7.25.2 Alcami Business Overview
- 7.25.3 Alcami Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.25.4 Alcami Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.25.5 Alcami Recent Development
- 7.26 Euroapi
- 7.26.1 Euroapi Company Details
- 7.26.2 Euroapi Business Overview
- 7.26.3 Euroapi Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.26.4 Euroapi Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.26.5 Euroapi Recent Development
- 7.27 Eurofins
- 7.27.1 Eurofins Company Details
- 7.27.2 Eurofins Business Overview
- 7.27.3 Eurofins Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.27.4 Eurofins Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.27.5 Eurofins Recent Development
- 7.28 Avid Bioservices
- 7.28.1 Avid Bioservices Company Details
- 7.28.2 Avid Bioservices Business Overview
- 7.28.3 Avid Bioservices Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.28.4 Avid Bioservices Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.28.5 Avid Bioservices Recent Development
- 7.29 BioVectra
- 7.29.1 BioVectra Company Details
- 7.29.2 BioVectra Business Overview
- 7.29.3 BioVectra Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.29.4 BioVectra Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.30 CPL
- 7.30.1 CPL Company Details
- 7.30.2 CPL Business Overview
- 7.30.3 CPL Contract Development and Manufacturing Organizations (CDMOs) Introduction
- 7.30.4 CPL Revenue in Contract Development and Manufacturing Organizations (CDMOs) Business (2021-2026)
- 7.30.5 CPL Recent Development
8 Industry Chain Analysis
- 8.1 Contract Development and Manufacturing Organizations (CDMOs) Value Chain
- 8.2 Contract Development and Manufacturing Organizations (CDMOs) Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Key Suppliers of Raw Materials
- 8.2.3 Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream (Customer) Analysis
- 8.5 Sales Model and Sales Channels
- 8.5.1 Contract Development and Manufacturing Organizations (CDMOs) Sales Model
- 8.5.2 Sales Channels
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.2 Data Source
- 10.2 Author Details
- 10.3 Disclaimer
샘플 요청 목록